Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr;80(5):495-500.
doi: 10.1007/s40265-020-01277-0.

Osilodrostat: First Approval

Sean Duggan  1
Affiliations
Review

Osilodrostat: First Approval

Sean Duggan. Drugs. 2020 Apr.

Abstract

Osilodrostat (Isturisa®) is an orally available small molecule 11β-hydroxylase inhibitor that is being developed by Novartis for the treatment of Cushing's disease. Based on results from a pivotal phase III trial, osilodrostat was approved in the EU for use in the treatment of endogenous Cushing's syndrome in adults and is under regulatory review in the USA for the treatment of Cushing's disease. This article summarises the milestones in the development of osilodrostat leading to this first approval.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Clin Drug Investig. 2017 May;37(5):465-472 - PubMed
    1. Pituitary. 2016 Apr;19(2):138-48 - PubMed
    1. J Clin Endocrinol Metab. 2019 Aug 1;104(8):3437-3449 - PubMed
    1. J Clin Endocrinol Metab. 2014 Apr;99(4):1375-83 - PubMed
    1. J Transl Med. 2014 Dec 10;12:340 - PubMed

MeSH terms

LinkOut - more resources